Labcorp Holdings Inc. (LH)

In the past six months, Labcorp's stock has experienced several notable events. As of May 8, 2026, the stock price was $253.73. Over the past 30 days, LH was down 6.38%, but up 5.34% over the past 12 months. The 52-week high was $293.72 (October 21, 2025), and the 52-week low was $239.67 (May 15, 2025). Labcorp reported its Q1 2026 earnings on April 30, 2026, with an adjusted EPS of $4.25, beating analyst estimates of $4.09. Revenue for Q1 2026 was $3.54 billion, exceeding estimates of $3.51 billion and representing a 5.8% year-over-year increase. Following these strong results, management raised its full-year 2026 guidance for adjusted EPS to $17.70-$18.35 and revenue guidance to approximately $14.7 billion-$14.8 billion. The company also announced a quarterly dividend of $0.72 per share, payable on June 11, 2026. In February 2026, Labcorp missed Q4 CY2025 sales expectations, though sales still rose 5.6% year-on-year to $3.52 billion. Its non-GAAP profit of $4.07 per share for Q4 CY2025 was above analysts' consensus estimates.

Labcorp's operations in routine and specialty diagnostic testing, as well as drug development services, suggest a relatively stable demand profile. Healthcare services, in general, tend to have consistent demand, though certain elective procedures or seasonal illnesses could introduce minor fluctuations. The company's Q1 2026 earnings report indicated steady diagnostics demand that management says supports continued growth. The Biopharma Laboratory Services segment also reported an expanding backlog of $8.6 billion, indicating consistent demand for its drug development solutions. The introduction of at-home test collection kits for various conditions also aims to expand healthcare access and potentially stabilize demand by offering more convenient options.

Labcorp Holdings, Inc. is a global life sciences company providing comprehensive laboratory services for diagnosis and healthcare decisions, operating in the Healthcare sector, specifically in the Diagnostics & Research industry. It has two main segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment offers routine and specialty testing, as well as health and wellness services. The Biopharma Laboratory Services segment provides drug development, medical device, and diagnostic development solutions, along with digital pathology solutions and online and mobile applications.

Labcorp operates one of the largest clinical laboratory networks globally, with operations in nearly 100 countries, primarily in the U.S. In the United States, Labcorp has approximately 2,200 patient service centers and more than 6,000 in-office phlebotomists. The company also has over 30 U.S. reference and specialty labs dedicated to diagnostic testing and more than 75 global labs focused on research, development, and clinical trial testing.

Labcorp has maintained a generally positive brand reputation, reflected in its recognition on several Forbes lists for 2026, including America's Best Employers For Company Culture (#368), America's Best Large Employers (#321), America's Best Companies (#250), and Most Trusted Companies in America (#265). The company's strategic collaborations, such as with the Children's Hospital of Philadelphia to accelerate pediatric diagnostics, contribute positively to its reputation. The nationwide launch of an FDA-approved PD-L1 companion diagnostic for ovarian cancer patients eligible for KEYTRUDA also highlights its commitment to advancing diagnostics. Labcorp's focus on AI, robotics, and digital pathology is seen as an effort to improve efficiency and advanced testing capabilities, which can enhance its competitive position.

Labcorp Holdings, Inc. is primarily owned by institutional shareholders (97.41%), with insiders holding 1.63% and retail investors 0.96%. The Vanguard Group, Inc. is the largest institutional shareholder, owning 9.85 million shares, representing 12.01% of the company. Other major institutional owners include BlackRock, Inc., Victory Capital Management Inc., State Street Corp, Allspring Global Investments Holdings, LLC, Geode Capital Management, Llc, Select Equity Group, L.P., Wellington Management Group Llp, Boston Partners, and Morgan Stanley. No single entity controls a majority of the company, with ownership concentrated among mutual funds, ETFs, and index holders.